Provided are modified virus-like particles (VLPs) of paramyxoviruses, compositions containing them, methods of using the VLPs for delivery of any particular protein of interest to any of a variety of cells, kits that contain expression vectors for making, using and detecting VLPs, and methods for screening for anti-viral compounds using the VLPs. The modified VLPs contain a contiguous recombinant polypeptide that contains i) all or a segment of a C-terminal domain of a paramyxovirus nucleocapsid protein and ii) a polypeptide sequence of a distinct protein. Non-covalent complexes of paramyxovirus M protein and fusion proteins that contain a C-terminal domain of a paramyxovirus nucleocapsid protein and a polypeptide sequence of a distinct protein are provided, as are non-covalent complexes of cells, and cell receptors, with modified VLPs.

Disclosed herein are nanostructures and their use, where the nanostructures include (a) a plurality of first assemblies, each first assembly comprising a plurality of identical first polypeptides; (b) a plurality of second assemblies, each second assembly comprising a plurality of identical second polypeptides, wherein the second polypeptide differs from the first polypeptide; wherein the plurality of first assemblies non-covalently interact with the plurality of second assemblies to form a nanostructures; and wherein the nanostructure displays multiple copies of one or more paramyxovirus and/or pneumovirus F proteins or antigenic fragments thereof, on an exterior of the nanostructure.

The present invention relates to a novel feline paramyxovirus. The paramyxovirus of the present invention is a (−)ssRNA virus and has in one aspect a genome which is complementary to the nucleic acid according to SEQ ID NO:1 or SEQ ID NO:8. The invention further relates to corresponding nucleic acids and polypeptides, antibodies and vaccines. Further, the invention relates to medical uses and diagnostic methods concerning the paramyxovirus of the invention.

Disclosed are chimeric polypeptides based on viral membrane fusion proteins. More particularly, the present invention discloses chimeric polypeptides that comprise a virion surface exposed portion of a viral fusion protein and a heterologous structure-stabilizing moiety, and to complexes of those chimeric polypeptides. The present invention also discloses the use of these complexes in compositions and methods for eliciting an immune response to a fusion protein of an enveloped virus, or complex of the fusion protein, and/or for treating or preventing an enveloped virus infection. The present invention further discloses the use of the heterologous structure-stabilizing moiety for oligomerizing heterologous molecules of interest.

This disclosure describes a number of different polypeptide sequences, and the nucleic acid sequences encoding such polypeptide sequences, that can be used alone or in combination as universal vaccines (e.g., against influenza A or influenza B in humans or influenza in swine).

The present invention relates to a novel feline paramyxovirus. The paramyxovirus of the present invention is a (-)ssRNA virus and has in one aspect a genome which is complementary to the nucleic acid according to SEQ ID NO:1 or SEQ ID NO:8. The invention further relates to corresponding nucleic acids and polypeptides, antibodies and vaccines. Further, the invention relates to medical uses and diagnostic methods concerning the paramyxovirus of the invention.

The present invention relates to vaccine composition comprising an immunologically effective amount of a viral fusion protein antigen, such as an RSV pre-fusion F protein, and a stabilizing amount of an antiviral compound, and to methods for preparing such vaccine compositions.

A vaccine delivery method is presented that includes a composition including as one component a slurry matrix that is a liquid at room temperature and a gel at physiological pH, physiological salt concentrations and/or physiological temperatures and as a second component one or more antigens. Also included are methods of inducing an immune response in a subject and vaccinating a subject by administering such compositions.

This invention relates to a method of treating a dog for canine diseases comprising administering to the dog therapeutically effective amounts of a vaccine, wherein the vaccine comprises viral antigens, a bacterin, or both, and wherein the vaccine is administered subcutaneously or orally according to the schedules provided herein.

A heat-resistant recombinant Newcastle Disease Virus vaccine strain rLS-tFib2-C capable of expressing truncated Fiber 2 protein of fowl adenovirus serotype 4 has been preserved at the China Center for Type Culture Collection, Wuhan University, Wuhan, China with the preservation number of CCTCC No. V202042.